Pharma major Lupin announced the launch of its Tydemy Tablets (Drospirenone, Ethinyl Estradiol, Levomefolate Calcium, 3mg/0.03mg/0.451mg and Levomefolate Calcium, 0.451mg) having received an approval from the United States Food and Drug Administration (FDA) earlier.

Lupin's Tydemy (Drospirenone, Ethinyl Estradiol, Levomefolate Calcium, 3mg/0.03mg/0.451mg & Levomefolate Calcium, 0.451mg) are the generic equivalents of Bayer HealthCare Pharmaceuticals Inc.'s Safyral tablets. It is indicated for use by women to prevent pregnancy and to raise folate levels in women who choose to use an oral contraceptive for contraception.

Drospirenone, EE, Levomefolate Calcium, 3mg/0.03mg/0.451mg & Levomefolate Calcium, 0.451mg tablets had annual sales of approximately USD 22 million in the US (IQVIA January 2018).

Shares of the company gained Rs 4.1, or 0.53%, to trade at  Rs 784.95.  The total volume of shares traded  was  5,849 at the BSE (9.29 a.m., Wednesday).